467-55-0
中文名稱
海柯吉寧
英文名稱
Hecogenin
CAS
467-55-0
EINECS 編號
207-392-4
分子式
C27H42O4
MDL 編號
MFCD00067285
分子量
430.62
MOL 文件
467-55-0.mol
更新日期
2024/10/28 09:53:20
467-55-0 結構式
基本信息
中文別名
?？录獙?BR>?？略磉霸?BR>?？略碥赵?BR>(25R)-5α-螺甾(烷)-3β-醇-12-酮(3β,5α,25R)-3-羥基螺甾(烷)-12-酮
海可吉寧
番麻皂素
辛酸己酯
核柯配基
?？杉獙?(25R)-5Α-螺甾(烷)-3Β-醇-12-酮
蕃麻皂甙元
蕃麻皂素
英文別名
25R,5ALPHA-SPIROSTAN-3BETA-OL-12-ONE3BETA-HYDROXY-5ALPHA-SPIROSTAN-12-ONE
5-ALPHA, 20-ALPHA, 22-ALPHA, 25D-SPIROSTAN-3-BETA-OL-12-ONE
5ALPHA-SPIROSTAN-3BETA-OL-12-ONE
HECOGENIN
(25R)-5-Spirostan-3-ol-12-one
Hecoginin
HECOGENIN 98.0% BY HPLC
(3,5,25R)-3-Hydroxysiprostan-1
(3,5,25R)-3-Hydroxysiprostan-12-one
HECOGENIN (3B-HYDROXY-5A-SPIROSTAN-12-ONE)
3β-Hydroxy-5α-spirostan-12-one, 5α-Spirostan-3β-ol-12-one
12-Oxotigogenin
3-b-Hydroxy-5-a-spirostan-12-one
(25R)-3β-Hydroxy-5α-spirostan-12-one
所屬類別
生物化工：提取物物理化學性質
外觀性狀結晶化合物（丙酮）。熔點 264-266℃。（有報道稱具三種晶形，熔點 245℃，253℃，268℃）[α]D+8°（氯仿）/-10°（二烷）。
熔點268°C
比旋光度7.2 º (c=0.8 g/100ml, CHCl3)
沸點464.85°C (rough estimate)
密度1.0040 (rough estimate)
折射率1.4840 (estimate)
儲存條件Sealed in dry,Room Temperature
溶解度可溶于氯仿（少許）、甲醇（少許）
酸度系數(shù)(pKa)15.10±0.70(Predicted)
形態(tài)固體
顏色白色至灰白色
Merck4622
CAS 數(shù)據(jù)庫467-55-0(CAS DataBase Reference)
?？录獙巸r格(試劑級)
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2024/08/19 | HY-N1422 | ?？录獙?BR>Hecogenin | 467-55-0 | 5mg | 280元 |
| 2024/08/19 | HY-N1422 | ?？录獙?BR>Hecogenin | 467-55-0 | 10mg | 400元 |
| 2024/08/19 | HY-N1422 | ?？录獙?BR>Hecogenin | 467-55-0 | 20mg | 620元 |
常見問題列表
生物活性
Hecogenin 是從龍舌蘭 (Agave sisalana) 分離的類固醇皂苷，是人 UDP-葡萄糖醛酸糖基轉移酶的選擇性抑制劑。Hecogenin 具有廣泛的藥理活性，包括抗炎，抗真菌和胃保護作用。靶點
| Target | Value |
|
UGT1A4
() | 1.5 μM |
體內研究
Hecogenin (3.1-90 mg/kg; oral administration; for 15 hours; male Swiss mice) acutely administered, before ethanol, exhibits a potent gastroprotective effect. The Hecogenin pretreatment normalizes GSH levels and significantly reduces lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Hecogenin also decreases MPO release and significantly protects the gastric mucosa.
| Animal Model: | Male Swiss mice (20-30 g) with ethanol |
| Dosage: | 3.1 mg/kg, 7.5 mg/kg, 15 mg/kg, 30 mg/kg, 60 mg/kg and 90 mg/kg |
| Administration: | Oral administration; for 15 hours |
| Result: | Normalized GSH levels and significantly reduced lipid peroxidation and nitrite levels in the stomach, as evaluated by the ethanol-induced gastric lesion model. Decreased MPO release and significantly protected the gastric mucosa. |